When to Initiate Antifungal Treatment in COVID-19 Patients with Secondary Fungal Co-infection

Pruthi, Harnoor Singh

doi:10.1007/s40588-022-00184-0

Cited by 3 publications

(1 citation statement)

References 53 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Death hazard ratio was 1.45 for CAPA patients compared with patients without CAPA. Although the differential diagnosis between colonization and CAPA can be a challenge, awareness is important to allow early antifungal treatment [ 88 , 89 ].…”

Section: Patientsmentioning

confidence: 99%

Invasive Pulmonary Aspergillosis

Ledoux

Herbrecht

2023

JoF

View full text Add to dashboard Cite

Invasive pulmonary aspergillosis is growing in incidence, as patients at risk are growing in diversity. Outside the classical context of neutropenia, new risk factors are emerging or newly identified, such as new anticancer drugs, viral pneumonias and hepatic dysfunctions. Clinical signs remain unspecific in these populations and the diagnostic work-up has considerably expanded. Computed tomography is key to assess the pulmonary lesions of aspergillosis, whose various features must be acknowledged. Positron-emission tomography can bring additional information for diagnosis and follow-up. The mycological argument for diagnosis is rarely fully conclusive, as biopsy from a sterile site is challenging in most clinical contexts. In patients with a risk and suggestive radiological findings, probable invasive aspergillosis is diagnosed through blood and bronchoalveolar lavage fluid samples by detecting galactomannan or DNA, or by direct microscopy and culture for the latter. Diagnosis is considered possible with mold infection in lack of mycological criterion. Nevertheless, the therapeutic decision should not be hindered by these research-oriented categories, that have been completed by better adapted ones in specific settings. Survival has been improved over the past decades with the development of relevant antifungals, including lipid formulations of amphotericin B and new azoles. New antifungals, including first-in-class molecules, are awaited.

show abstract

Section: Patientsmentioning

confidence: 99%

Invasive Pulmonary Aspergillosis

Ledoux

Herbrecht

2023

JoF

View full text Add to dashboard Cite

show abstract

Is there an interest in systematic serum screening for aspergillosis in COVID-19 patients in a medical ward?

Gerber,

Boehn,

Sabou

et al. 2024

Infectious Diseases Now

View full text Add to dashboard Cite

The Role of COVID-19 in Antibiotic Resistance in Pediatric Population

et al. 2023

View full text Add to dashboard Cite

There is data on the irrational use of antimicrobial drugs in pediatric population during the COVID-19 pandemic. This could lead to potential development of antibiotic resistance and increased morbidity and mortality among this vulnerable population group. The aim of this review is to study the role of COVID-19 in antimicrobial drugs administration and antibiotic resistance development, as well as to determine a set of measures for its prevention. Recent studies results have shown that COVID-19 pandemic had both direct and indirect impact on antibiotic resistance development in pediatric population. The COVID-19 outbreak has revealed weaknesses in health systems around the world. Antibiotics administration in patients with coronavirus infection during this period exceeded the number of cases with bacterial co-infection or other diseases. Thus, it indicates irrational antibiotic treatment. There were cases of inappropriate antibiotics administration during the crisis caused by the COVID-19 pandemic even in regions with long-term rational antibiotic treatment programs. One of the most viable methods to combat antibiotic resistance is to improve approaches in health care and to increase preparedness to infectious outbreaks. Increasing clinical competence of medical workers, accessibility of medical facilities, permanent supply of high-quality and cheap antibiotics, vaccines, reducing COVID-19 testing time, and adequate administration of antibacterial agents are the measures that can prevent diseases caused by drug resistance. All stakeholders (health authorities, regulating authorities, politicians, scientific community, pharmaceutical companies) have to collaborate and achieve results to implement all the mentioned above protection measures.

show abstract

When to Initiate Antifungal Treatment in COVID-19 Patients with Secondary Fungal Co-infection

Cited by 3 publications

References 53 publications

Invasive Pulmonary Aspergillosis

Invasive Pulmonary Aspergillosis

Is there an interest in systematic serum screening for aspergillosis in COVID-19 patients in a medical ward?

The Role of COVID-19 in Antibiotic Resistance in Pediatric Population

Contact Info

Product

Resources

About